|

Pirtobrutinib Clinical Trials

26 actively recruiting trials across 17 locations

Also known as: 5-Amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-((2S)-1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide, BTK Inhibitor LOXO-305, Jaypirca, LOXO 305, LOXO-305 +4 more

Pipeline

Early 1: 1Phase 1: 1Phase 2: 19Phase 3: 2Phase 4: 2Phase 1/2: 1

Top Sponsors

  • M.D. Anderson Cancer Center5
  • Eli Lilly and Company3
  • Loxo Oncology, Inc.2
  • Inhye Ahn2
  • University of Washington1

Indications

  • Cancer26
  • Chronic Lymphocytic Leukemia11
  • Mantle Cell Lymphoma7
  • Small Lymphocytic Lymphoma6
  • Non-hodgkin Lymphoma4

Other4 trials

A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.
Phase 2
Clonal Dynamics of Chronic Lymphocytic Leukaemia Treated With Pirtobrutinib After Previous Treatment With Zanubrutinib
Phase 2
Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers
Phase 2
Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL
Phase 2

Houston, Texas4 trials

Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).

MD Anderson Cancer Center

Phase 2
Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients

M D Anderson Cancer Center

Phase 2
Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients

MD Anderson Cancer Center

Phase 2
Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)

M D Anderson Cancer Center

Phase 2

Boston, Massachusetts3 trials

A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)

Beth Israel Deaconess Medical Center (Data Collection Only)

Phase 2
Mosunetuzumab for CLL MRD Clearance

Brigham & Women's Hospital

Phase 1/2
Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia

Beth Israel Deaconness Medical

Phase 2

Chandler, Arizona1 trial

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Ironwood Cancer & Research Centers

Phase 2

Phoenix, Arizona1 trial

A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Mayo Clinic Phoenix

Phase 3

Anaheim, California1 trial

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Pacific Cancer Medical Center, Inc

Phase 3

Davis, California1 trial

Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

University of California, Davis

Phase 2

Stanford, California1 trial

Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL

Stanford Cancer Center

Phase 2

Jacksonville, Florida1 trial

A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

Cancer Specialists, LLC

Phase 4

Miami, Florida1 trial

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

Sylvester Comprehensive Cancer Center

Phase 4

Atlanta, Georgia1 trial

Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

Winship Cancer Institute at Emory University

Phase 2

Scarborough, Maine1 trial

Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia

New England Cancer Specialists

Phase 2

Bethesda, Maryland1 trial

Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib

National Institutes of Health Clinical Center

Early 1

Rochester, Minnesota1 trial

GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma

Mayo Clinic in Rochester

Phase 2

St Louis, Missouri1 trial

Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)

Washington University

Phase 2

Columbus, Ohio1 trial

Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi

Ohio State University Comprehensive Cancer Center

Phase 2

Seattle, Washington1 trial

Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial

Fred Hutch/University of Washington Cancer Consortium

Phase 2

Milwaukee, Wisconsin1 trial

LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies

Froedtert & the Medical College of Wisconsin

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.